ERBB2 and breast carcinoma: The finding that the co-occurrence of BRCA1/2 mutations and a HER2-positive status is associated with worse OS in patients with early or locally advanced breast cancer may be proof of concept that a combined pharmacological intervention directed to these targets could be synergistic.